港股收評:恆指跌0.63%24000點失而復得, 創新藥概念股繼續大漲
港股三大指數午後跌幅有所收窄,早盤曾跌超1.2%以上,市場總體表現低迷,前期大漲的板塊有所回調。截止收盤,恆指跌0.63%24000點失而復得,國企指數、恆生科技指數分別下跌0.88%及0.67%。盤面上,大型科技股普遍走低,小米跌3.4%,阿里巴巴跌近3%,美團跌2.5%,京東跌超2%,騰訊飄綠;昨日午後因傳聞飆漲的鋼鐵股集體回落,重慶鋼鐵股份大跌超23%昨日飆漲超91%,馬鞍山鋼鐵跌近5%;新消費概念股、穩定幣概念股、教育股、內銀股等熱門板塊走低,其中奈雪的茶跌超10%,蜜雪集團、泡泡瑪特跌超3%。另一方面,美越達成貿易協定,機構稱消費電子壓制因素有望修復,蘋果概念股午後拉昇明顯;創新藥概念股午後加速上漲,華昊中天醫藥尾盤飆漲超55%,康方生物漲超14%,信達生物、三生製藥等皆有漲幅。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.